根据美国证券交易委员会(SEC)提交的文件,Adial Pharmaceuticals 预计在股东批准后,将迎来董事会重组,并面临多位资深成员辞职的局面。
根据美国证券交易委员会(SEC)提交的文件,Adial Pharmaceuticals 预计在股东批准后,将迎来董事会重组,并面临多位资深成员辞职的局面。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.